STARBOARD: encorafenib + binimetinib + pembrolizumab for first-line metastatic/unresectable
Antibodies, Monoclonal, Humanized
Antineoplastic Combined Chemotherapy Protocols
/ adverse effects
Benzimidazoles
Carbamates
Humans
Melanoma
/ drug therapy
Mutation
Neoplasms, Second Primary
/ etiology
Protein Kinase Inhibitors
/ therapeutic use
Proto-Oncogene Proteins B-raf
/ genetics
Randomized Controlled Trials as Topic
Skin Neoplasms
/ drug therapy
Sulfonamides
BRAF V600 mutations
advanced melanoma
binimetinib
encorafenib
immunotherapy
pembrolizumab
targeted therapy
triplet combination therapy
Journal
Future oncology (London, England)
ISSN: 1744-8301
Titre abrégé: Future Oncol
Pays: England
ID NLM: 101256629
Informations de publication
Date de publication:
Jun 2022
Jun 2022
Historique:
pubmed:
12
3
2022
medline:
6
5
2022
entrez:
11
3
2022
Statut:
ppublish
Résumé
Despite the significant progress in the treatment of unresectable or metastatic Targeted therapy, including BRAF- and MEK-inhibitors, and immunotherapies have greatly contributed to advances in the treatment of
Autres résumés
Type: plain-language-summary
(eng)
Targeted therapy, including BRAF- and MEK-inhibitors, and immunotherapies have greatly contributed to advances in the treatment of
Identifiants
pubmed: 35272485
doi: 10.2217/fon-2021-1486
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
Benzimidazoles
0
Carbamates
0
Protein Kinase Inhibitors
0
Sulfonamides
0
binimetinib
181R97MR71
encorafenib
8L7891MRB6
pembrolizumab
DPT0O3T46P
BRAF protein, human
EC 2.7.11.1
Proto-Oncogene Proteins B-raf
EC 2.7.11.1
Banques de données
ClinicalTrials.gov
['NCT04657991']
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
2041-2051Subventions
Organisme : Pfizer